Genomeden Global: A Free E-Magazine ’s Post

HEALTH MATTERS: Six types of cancer are linked to alcohol consumption: head and neck cancers, esophageal cancer, liver cancer, breast cancer, colorectal cancer, and stomach cancer. https://lnkd.in/e89cqe3v

Pursuing a keto diet or ketone supplement pre intervention made prostate cancer more recognizable to the immune system, leading to more successful treatment with immunotherapy- exciting! Perhaps something that could translate into other areas of cancer research to improve outcomes. Per the study author “It also underscores the importance of continued research into the interplay between diet, metabolism and immune function in cancer therapy.” #immunotherapy #cancerresearch #watchthisspace

A rather nice review on the companies involved with CAR-T targeting lupus. As lupus is a B-Cell dependent disease where overproduction of autoimmune immunogloblins are made, one potential way to treat the disease is to ablate the B cells. Hence the pivot from CAR-T treating B cell cancers to treating lupus is not that far removed. Unlike cancer, lupus is more chronic, and many other treatment modalities are available. Time will tell if such new therapies will offer patients greater hope in managing their disease. This article summarizes the biopharma companies actively involved in this effort. " The study showed a cellular medicine could drive a tough-to-treat form of lupus into remission. While early, the finding suggested a technique used to create powerful cellular treatments for cancer might also work against autoimmune conditions like lupus, too. “It’s very early days, but it’s exciting for the field to see this possibility,” said cell therapy pioneer and University of Pennsylvania immunologist Carl June, in an interview at the time. " https://lnkd.in/ern_eCVD Disclaimer- views expressed here are of the Author only

Pro-Oxidant Supplement Halts Prostate Cancer Progression in Mice: • A research team led by Lloyd Trotman from Cold Spring Harbor Laboratory (CSHL) has discovered that the pro-oxidant supplement menadione, a precursor to vitamin K, can slow prostate cancer progression in mice. This finding challenges the conventional wisdom that antioxidants are beneficial for cancer prevention and treatment, as previous studies have shown that antioxidant supplements may actually promote cancer growth. • Menadione works by interfering with the cancer's survival processes, specifically by depleting a lipid called PI(3)P which is essential for the recycling of incoming materials within the cells. Without PI(3)P, the cells eventually burst and die. • Trotman's team hopes to translate their findings into pilot studies involving human prostate cancer patients, and they also believe that menadione may have potential in treating myotubular myopathy, a rare condition that affects muscle growth in infant boys. #Medicine #prostatecancer #cancer #oncology #drugdiscovery #innovative #therapies #pharmaceuticalindustry #drugdevelopment

Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes « In this study, GLP-1RAs were associated with lower risks of specific types of obesity-associated cancers compared with insulins or metformin in patients with T2D. These findings provide preliminary evidence of the potential benefit of GLP-1RAs for cancer prevention in high-risk populations and support further preclinical and clinical studies for the prevention of certain obesity-associated cancers ». #GLP1 #cancer #publichealth #pharmacology #obesity https://lnkd.in/e-UrTp_w

I am super happy to share the first publication of my PhD! Please check it out if you want to know more about the role of a novel glyco-immune checkpoint in melanoma and how to target it to improve therapies against this cancer! Thanks to my supervisors Yvette van Kooyk and Fabrizio Chiodo for the great feedback and support, and to the MSCA GLYTUNES network for funding our work. #immunotherapy #melanoma #glycoscience #immunecheckpoint #glycotime

How can dietary intervention of omega-3 fatty acids help to enhance the efficacy of immunotherapy targeting multiple cancer types? Dr. Weicang Wang is collaborating with Harvard Medical School and UC Davis to explore this idea. Additionally, this work implicates the stabilization of omega-3 fatty acid-derived lipid mediators as a promising strategy in cancer therapy. Read more about this high-impact research: https://lnkd.in/gZV-iMs6

🎉 Hot off the press! Our latest article just got published in PNAS! This research sheds light on the intricate relationship between MUC1, a protein overexpressed in pancreatic cancer, and polyamine metabolism, a critical factor in cancer development. Our findings reveal how MUC1 regulates key enzymes of polyamine pathway, influencing cell survival, proliferation, and therapy resistance. Importantly, we demonstrate that targeting polyamine metabolism can enhance the efficacy of existing FOLFIRINOX treatment, offering new hope for pancreatic cancer therapy. Read more about our study here: https://lnkd.in/gcfJbEdz #CancerResearch #PancreaticCancer #PNAS #Innovation

🚨This edition of BioWire Weekly gives briefs on significant developments in the biotech industry, including discussion on obesity combo therapies, Malaria preventative treatments, the first fetal kidney transplant, and two new cancer therapeutics. How will these advancements shape the future of medicine? https://lnkd.in/gWcX4yRs

🌟 Roche Wins FDA Nod for Breast Cancer Drug in First-Line Setting🌟 Exciting news in the fight against breast cancer! Roche has announced that the FDA has approved their pipeline candidate, inavolisib, under the brand name Itovebi. This approval marks a significant advancement in breast cancer treatment. 🎗️💊 Key Highlights: - Combination Therapy: Itovebi is approved in combination with Pfizer’s Ibrance (palbociclib) and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer¹². - Targeted Treatment: This combination therapy is designed for patients whose disease has recurred on or after completing adjuvant endocrine therapy, addressing a critical unmet need in breast cancer treatment¹². Clinical Impact: - Improved Outcomes: The approval is based on Phase III INAVO120 results, showing that the Itovebi-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting¹². - Patient Benefit: This new treatment option offers hope for better management of HR-positive, HER2-negative breast cancer, particularly for those with the PIK3CA mutation, which is associated with poor prognosis¹². Join the Conversation: What are your thoughts on this new approval? How do you see this impacting the future of breast cancer treatment? Share your insights and let's discuss! 💬👇 #BreastCancer #FDAApproval #CancerTreatment #Healthcare #Innovation #Roche #Pfizer #Pharmaceuticals #MedicalLaboratoryTechnology #Microbiology #Phlebotomy #LaboratoryTesting #DiagnosticTesting #HealthcareProfessional #MedicalTesting #ClinicalLaboratory #BiomedicalScience #HealthcareIndustry #MedicalScience #LaboratoryMedicine #ClinicalMicrobiology #InfectionControl #PhlebotomyTechnician #MedicalLabTechnician #MicrobiologyLab #ClinicalLab #HealthcareCareer #MedicalCareer #ScienceCareer #COVID19Testing #Virology #Bacteriology #Parasitology #MolecularDiagnosis #GeneticTesting #Cytology #Histopathology #Immunology #Serology